Biomunex Pharmaceuticals, a biopharmaceutical company specializing in the development of next generation immunotherapies based on the discovery and development of bispecific and multispecific ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Tumor tissue from 868 patients in the QUASAR ...
P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable ...
CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 has ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...
Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.
This article is based on a poster originally authored by Weiping Sun, Xing Zhang, Zhaolu Yan, Chen Yu, Spencer Chiang, and Tianfu Zhang. Immunotherapy is an advanced and widely used treatment due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback